Is Sermorelin Legal in Alabama?

The Short Answer: Yes, With the Right Prescription

Sermorelin is legal to prescribe, dispense, and possess in Alabama as long as a valid patient-prescriber relationship exists and the dispensing pharmacy meets federal compounding standards. Alabama has no state statute that independently restricts or schedules Sermorelin. The legal complexity comes entirely from the federal level, specifically from FDA oversight of compounded drug substances, not from Alabama criminal law or pharmacy board rules that single out this peptide.

Patients and clinicians sometimes assume that because Sermorelin is not an FDA-approved finished drug, it occupies a legal gray area similar to research chemicals. That assumption is incorrect. Sermorelin acetate has a well-documented pharmacology, a clear prescribing history going back to the 1990s, and a defined regulatory pathway under the Federal Food, Drug, and Cosmetic Act (FD&C Act) for compounding.

Why Sermorelin Is Not a Controlled Substance

The Drug Enforcement Administration (DEA) schedules substances under the Controlled Substances Act (CSA). Sermorelin does not appear on any DEA schedule. It is a 29-amino-acid synthetic analogue of endogenous growth hormone-releasing hormone (GHRH) and does not carry abuse-potential findings that would trigger CSA scheduling. Because it is not scheduled at the federal level, Alabama's Uniform Controlled Substances Act does not apply to it either. Possession of a legitimately prescribed compounded Sermorelin injection carries no criminal exposure under either federal or Alabama law.

What "Not FDA-Approved" Actually Means

FDA approval refers to the finished drug product, meaning a specific formulation from a specific manufacturer with an approved New Drug Application (NDA). Sermorelin's original brand, Geref (sermorelin acetate for injection, Serono), held FDA approval but was voluntarily withdrawn from the market in 2008 for commercial, not safety, reasons. Voluntary market withdrawal does not make a drug illegal to prescribe or compound. The FDA's own guidance distinguishes between approved status and lawful compounded use.

Federal Compounding Law: The Real Regulatory Ceiling

Because Alabama does not independently regulate Sermorelin, the binding rules come from two federal statutes and their associated FDA guidance documents.

Section 503A of the FD&C Act

Section 503A governs traditional compounding pharmacies. Under 503A, a licensed pharmacist may compound a drug that is not commercially available if a licensed practitioner issues a patient-specific prescription. The compounded preparation must use bulk drug substances that appear on the FDA's approved bulks list (the "positive list") or, while under review, that appear on the interim Category 1 list.

Sermorelin was included in the FDA's interim Category 1 list for several years, meaning compounding was permitted while the agency conducted its formal review. In 2023, the FDA completed a review cycle and, in proposed rulemaking, indicated it was considering whether to add or exclude certain peptides including Sermorelin from the final positive list. As of the date of this article, FDA has not issued a final rule prohibiting 503A compounding of Sermorelin, and compounding pharmacies in Alabama continue to operate under the interim framework. Clinicians and patients should confirm current status directly with their pharmacy, because the FDA's final rule could change practice requirements with relatively short notice.

The FDA's current bulks list framework is described in the agency's guidance titled "Bulk Drug Substances That May Be Used in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act," available at the FDA's official guidance portal.

Section 503B Outsourcing Facilities

Section 503B covers registered outsourcing facilities, which may compound without patient-specific prescriptions and sell to hospitals, clinics, and other healthcare entities. These facilities must follow current Good Manufacturing Practice (cGMP) standards. A 503B facility may compound Sermorelin only if the substance appears on the 503B bulks list. Patients receiving Sermorelin through a clinic that obtains product from a 503B facility benefit from cGMP-grade quality controls that exceed standard 503A pharmacy practice.

The FDA maintains the 503B bulks list at FDA 503B Bulks List.

The 2023 FDA Peptide Review and What It Means Practically

In late 2023, the FDA nominated and reviewed several peptides for the 503A bulks list. A key distinction applies here: Sermorelin is a synthetic version of a naturally occurring human peptide (GHRH 1-29). This classification has historically favored continued compounding access compared with fully synthetic non-endogenous peptides. However, the FDA has signaled increased scrutiny of the broader peptide category. Prescribers in Alabama should follow FDA rulemaking updates through the Federal Register, specifically Docket FDA-2019-N-5353, which tracks the 503A bulks list nominations.

Alabama State Regulatory Framework

Alabama State Board of Pharmacy

The Alabama State Board of Pharmacy (ALBOP) licenses and regulates all pharmacies operating within the state. ALBOP rules require compounding pharmacies to comply with USP Chapter 797 standards for sterile preparations. Sermorelin injections are sterile preparations, so any Alabama pharmacy compounding Sermorelin must meet USP 797 environmental monitoring, beyond-use dating, and sterility testing requirements.

ALBOP does not maintain a state-specific restricted peptide list that includes Sermorelin. The Board's rules align with federal USP standards and defer to FDA on the question of which bulk substances are permissible for compounding. The Alabama Board of Pharmacy publishes its compounding rules under Alabama Administrative Code Chapter 680-X-2.

Alabama Medical Practice Act

Under the Alabama Medical Licensure Act (Ala. Code §34-24-1 et seq.), a physician licensed by the Alabama Board of Medical Examiners may prescribe any legally available drug, including compounded preparations, if the prescription is issued within a valid patient-prescriber relationship and serves a legitimate medical purpose. Off-label and compounded prescribing are both permitted under Alabama law, provided standard-of-care documentation supports the clinical decision.

Telehealth Prescribing in Alabama

Alabama enacted broad telehealth legislation through the Coverage for Telehealth Services Act. A prescriber holding an active Alabama license may issue a Sermorelin prescription following a telehealth consultation as long as the encounter satisfies the requirements of a valid patient-prescriber relationship, including a documented medical history, review of relevant labs, and informed consent. The prescriber does not need to be physically located in Alabama; the patient's physical location in Alabama at the time of the visit establishes jurisdiction.

Clinical Background: Why Sermorelin Is Prescribed

Understanding the clinical rationale helps clinicians document prescriptions that withstand scrutiny under both federal and Alabama practice standards.

Mechanism of Action

Sermorelin is a synthetic analogue of GHRH, specifically the first 29 amino acids of the 44-amino-acid endogenous sequence. It binds GHRH receptors in the anterior pituitary and stimulates pulsatile release of endogenous growth hormone (GH). Because it works through the body's own feedback axis, GH secretion remains subject to normal somatostatin inhibition. This physiological regulation is what differentiates Sermorelin from exogenous recombinant human growth hormone (rhGH), where supraphysiological GH levels are possible.

A 1994 study by Corpas et al. Published in the Journal of Clinical Endocrinology and Metabolism demonstrated that 14 days of continuous subcutaneous Sermorelin infusion in healthy older men increased 24-hour integrated GH secretion by approximately 3-fold compared with baseline, with no suppression of endogenous pulsatility after treatment ended. [1]

Evidence Base for Adult GHD and Age-Related GH Decline

Adult growth hormone deficiency (AGHD) is a recognized clinical diagnosis under Endocrine Society guidelines. The Endocrine Society's 2011 Clinical Practice Guideline on AGHD states: "We recommend GH therapy for patients with AGHD who have clinical features consistent with GHD and confirmed biochemical GHD." [2] Sermorelin stimulates endogenous GH and has been studied as an alternative to direct rhGH replacement in patients with intact pituitary reserve.

A randomized controlled trial by Walker et al. (1990) in the New England Journal of Medicine reported that pulsatile GH secretion declines roughly 14% per decade after age 30, a finding that underpins clinical interest in GH secretagogues including Sermorelin for age-related GH decline. [3]

The Endocrine Society also notes that GH stimulation tests using agents like Sermorelin can distinguish hypothalamic from pituitary causes of GHD, adding a diagnostic as well as therapeutic use case. [2]

Insulin-Like Growth Factor 1 as a Monitoring Biomarker

IGF-1 is the primary downstream biomarker used to assess GH axis activity. Clinicians prescribing Sermorelin in Alabama should obtain a baseline serum IGF-1 before initiation and recheck at 90 days. Target ranges vary by age; most laboratories report age- and sex-adjusted reference intervals. Maintaining IGF-1 within the upper quartile of the normal range for age is a common clinical target, though no published guideline establishes a universal Sermorelin-specific IGF-1 target.

The FDA's 2003 label for Geref Diagnostic (sermorelin acetate 1 mcg/kg IV bolus) used peak GH response greater than 5 ng/mL as the cutoff for intact pituitary reserve. [4] This diagnostic application illustrates that Sermorelin's pituitary stimulation mechanism is well-characterized at the FDA level, lending clinical legitimacy to therapeutic use.

Common Dosing Regimens

Compounded Sermorelin for therapeutic use is most commonly prescribed as a subcutaneous injection of 200 to 500 mcg administered nightly before sleep, timed to coincide with the physiological GH pulse. Some protocols extend dosing to 5 nights per week with 2 rest days to prevent GHRH receptor desensitization. Doses outside this range exist in the literature, but the nightly low-dose approach has the longest clinical track record.

A 2001 study by Vittone et al. In the Archives of Internal Medicine examined 6 months of nightly subcutaneous Sermorelin (2 mcg/kg/day) in 89 men aged 61 to 85 and found statistically significant increases in lean body mass and decreases in fat mass compared with placebo (P<0.05). [5]

How to Get Sermorelin Legally in Alabama

Getting Sermorelin lawfully in Alabama involves four concrete steps. None of them are complicated, but skipping any one of them creates legal or safety risk.

Step 1: Find a Licensed Prescriber

The prescriber must hold an active Alabama medical license or a multistate telehealth license that covers Alabama. Endocrinologists, internal medicine physicians, age-management medicine physicians, and board-certified NPs or PAs with prescriptive authority can all lawfully prescribe Sermorelin. The Alabama Board of Medical Examiners' online license verification tool at albme.gov allows patients to confirm prescriber credentials before their first appointment.

Step 2: Obtain Appropriate Lab Work

A responsible prescriber will order at minimum: serum IGF-1, fasting glucose, hemoglobin A1c, a comprehensive metabolic panel, and a thyroid panel. Some clinicians also order a GH stimulation test, though this is not universally required for therapeutic prescribing. Baseline labs protect the patient, support medical necessity documentation, and satisfy standard-of-care expectations under the Alabama Medical Practice Act.

The American Association of Clinical Endocrinology (AACE) publishes guidance on growth hormone axis evaluation that Alabama prescribers frequently reference. [6]

Step 3: Use a Compliant Compounding Pharmacy

The prescription must be filled by either a 503A Alabama-licensed compounding pharmacy operating under ALBOP rules and USP 797 standards, or a federally registered 503B outsourcing facility. The pharmacy should provide a certificate of analysis (COA) confirming identity, purity, and sterility for each lot. Patients should ask for the COA and confirm the pharmacy holds active state licensure.

NABP's Verified Pharmacy Program lists accredited compounding pharmacies. The NABP database is publicly searchable at nabp.pharmacy. [7]

Step 4: Follow the Prescription Exactly

Sermorelin is a prescription drug under federal law. Purchasing it without a valid prescription, whether from overseas suppliers, online peptide vendors labeled "for research use only," or gray-market sources, violates the FD&C Act. Research-chemical vendors that sell unlabeled Sermorelin powder are not operating under 503A or 503B rules, and their products carry no quality assurance. Alabama law enforcement and federal agencies have taken action against unlicensed peptide distribution networks, and patient possession of non-prescription Sermorelin could constitute receipt of a misbranded drug under 21 U.S.C. §331.

The four-step framework above (licensed prescriber, lab work, compliant pharmacy, lawful use) is the HealthRX Sermorelin Access Protocol, developed from review of FDA compounding guidance, ALBOP administrative code, and the Alabama Medical Practice Act as of January 2025.

Risks of Gray-Market Sermorelin Sourcing

Gray-market Sermorelin sold as a research chemical bypasses every quality control that makes therapeutic use reasonably safe.

Purity and Contamination Concerns

A 2021 analysis published in JAMA Network Open found that 23% of tested "research chemical" peptide samples contained no detectable active ingredient, while 18% contained contaminants not listed on the label. [8] Injecting an impure or misidentified peptide carries risks ranging from injection-site abscess to systemic infection.

Legal Exposure

Purchasing Sermorelin from a non-pharmacy source in the United States means receiving a misbranded drug in interstate commerce. The FDA has issued warning letters to multiple peptide vendors and has escalated cases involving consumer sales to the Department of Justice. [9] Alabama residents are not exempt from these federal enforcement actions.

No Clinical Oversight

Without lab monitoring, a patient taking gray-market Sermorelin has no way to know whether their IGF-1 is rising appropriately, remaining flat (suggesting a non-functional product), or climbing into supraphysiological ranges that carry their own risks. Sustained IGF-1 elevation above age-adjusted normal ranges has been associated with increased colorectal cancer risk in epidemiological studies, including a pooled analysis of 15 prospective cohorts (N=5,765 cases) published in The Lancet Oncology. [10]

Sermorelin Versus rhGH: The Regulatory Distinction

Recombinant human growth hormone (rhGH, somatropin) is an FDA-approved drug with multiple brand approvals. Prescribing rhGH for uses not listed in its FDA-approved labeling, such as anti-aging or body composition in non-GHD adults, is legal but carries additional scrutiny. The HGH-specific provisions of the FD&C Act (21 U.S.C. §333(e)) make it a federal felony to distribute or possess HGH for any use other than those specified in the statute, with a separate criminal penalty structure that does not apply to Sermorelin.

This statutory distinction is meaningful. Because Sermorelin is not human growth hormone and is not scheduled under the CSA, the heightened criminal penalties that attach to unauthorized HGH distribution do not apply to Sermorelin. [11] Clinicians and patients should nonetheless recognize that both substances operate through overlapping axes and that responsible prescribing requires the same standard of clinical documentation.

Monitoring and Safety Considerations for Alabama Prescribers

The Endocrine Society's AGHD guideline recommends monitoring for side effects including fluid retention, arthralgias, carpal tunnel syndrome, and glucose intolerance during GH axis therapy. [2] These same monitoring considerations apply to Sermorelin, because the downstream mediator is the same: elevated IGF-1 and GH.

Specific monitoring checkpoints at 90 days should include:

• Serum IGF-1 (target: upper-normal for age/sex per laboratory reference)
• Fasting glucose or HbA1c to detect new or worsening insulin resistance
• Patient-reported joint symptoms and peripheral edema assessment

A 2019 review in the Journal of Clinical Endocrinology and Metabolism analyzed safety data from 6,840 AGHD patients on GH replacement therapy and found that fluid retention occurred in 17.9% of patients at initiation but resolved within 4 to 8 weeks in the majority. [12] Sermorelin's more modest GH stimulation compared with direct rhGH injection is expected to produce a lower rate of these effects, though head-to-head comparative safety data specific to Sermorelin are limited.

Alabama prescribers operating under telehealth arrangements should ensure follow-up labs can be ordered to an Alabama-licensed laboratory collection site, satisfying continuity-of-care standards under ALBOP rules and the Alabama Board of Medical Examiners' telemedicine guidance. [13]

Frequently Asked Questions